The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules
While 2021 ended with the world engulfed in the COVID-19 Omicron wave, 2022 has ended in almost all countries, except China, with COVID-19 being likened to the flu. In this context, the U.S. Food and Drug Administration (FDA) has authorized only 37 new drugs this year compared to an average of 52 in...
Main Authors: | Beatriz G. de la Torre, Fernando Albericio |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-01-01
|
Series: | Molecules |
Subjects: | |
Online Access: | https://www.mdpi.com/1420-3049/28/3/1038 |
Similar Items
-
The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2024-01-01) -
The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2021-01-01) -
The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules
by: Beatriz G. de la Torre, et al.
Published: (2022-02-01) -
Chemistry and Pharmacology of Fluorinated Drugs Approved by the FDA (2016–2022)
by: Ghulam Shabir, et al.
Published: (2023-08-01) -
FDA Approvals of Biologics in 2022
by: Alexander C. Martins, et al.
Published: (2023-05-01)